Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

INTERLACE

- PMLiVE

GSK files combination skin cancer drug in US

Seeks FDA approval for Tafinlar - Mekinist combination in melanoma

- PMLiVE

The rise of chronic disease in BRIC markets

Changing disease patterns in the BRIC nations are providing new opportunities for growth

- PMLiVE

FDA grants orphan status to Activartis’ brain cancer immunotherapy

Regulator says AV0113 has potential in rare cancer malignant glioma

- PMLiVE

Roche’s Perjeta on US fast-track for early breast cancer

FDA grants priority review for drug's use before surgery

- PMLiVE

Merck Serono pushes into immunotherapies for cancer

Pharma company sets up dedicated R&D unit

Bayer symbol

Bayer signs $520m cancer alliance with Seattle Genetics

Will focus on development of antibody-drug conjugates

National Institute for Health and Care Excellence NICE logo

UK backs use of drugs to prevent breast cancer

Daily use of tamoxifen or raloxifene recommended in at-risk women

- PMLiVE

Astellas wins EU approval for prostate cancer drug Xtandi

Will compete with J&J’s big-selling Zytiga

- PMLiVE

Cost deters NICE from Sanofi’s bowel cancer drug Zaltrap

Fails to win recommendation despite patient access scheme

- PMLiVE

Sanofi and AstraZeneca form cancer research alliances with non-profits

Will work respectively with Curie Institute in France and Cancer Research UK

- PMLiVE

J&J acquires oncology candidate in $1bn Aragon buy

ARN-509 is in phase II development for castration resistant prostate cancer

- PMLiVE

Men’s oesophageal cancer risk “triple that of women”

New data from Cancer Research UK shines slight on 'quiet epidemic'

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links